This study was run to understand variations in treatment with resulting shifts in care management that aligns with patient preferences and migraine-specific care and observe if a relationship exists between racially diverse patients seeking care and healthcare provider (HCP) specialties, including alternative medicine providers. Diane Faraone, PharmD, Karina D’Angelo PhD., Andreas Lysandropoulos, MD, PhD. Background…

Winning the Long Game: Life Science Companies Must Focus on Market Access – Not Just Clinical Trials Life Science Clinical trials are just the start. Discover how real-world data help life sciences companies implement market access strategies designed to get new drugs to patients who need them. It takes life sciences companies a long time…

From evidence to adoption: How real-world data is powering digital health success Digital Health In today’s outcomes-driven healthcare landscape, real-world data (RWD) and real-world evidence (RWE) have emerged as critical tools to demonstrate clinical value, return on investment (ROI) and long-term impact beyond controlled trial environments. High-quality, analysis-ready data on real-world effectiveness is no longer…

Generic drugs don’t usually grab headlines. They’re dependable, low-cost and mostly stay in the background. But behind that generic label is a global system that’s far more fragile, and far more important, than it seems. Today, that system is under serious pressure. The United States is facing everything from supply chain disruptions and political instability…

This research, led by Grace K. Kane, Douglas Londono, and Nathan J. Markward, explores how the timing of biomarker testing affects survival outcomes in patients with non-small cell lung cancer (NSCLC). Using real-world claims data, it identifies disparities in testing and treatment patterns and their impact on mortality rates. Biomarker testing is essential to advancing…

Upping the Migraine Intelligence Quotient: Real-world data sheds light on prevalence rates, providers and treatment variation Life Sciences  Introduction Headache disorders including migraine are highly prevalent globally, estimated to affect more than 50% of the population at any point and time. In the U.S., migraine patients spend an average of $9,000 more than those without…

Using non-small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey.

At ISPOR 2025 in Montreal, PurpleLab presented a research poster titled “Trends in Attainment of the Kidney Health Evaluation for Patients with Diabetes Measure among Insured Individuals in the US, 2021-2024”. The study, conducted by Stephan Dunning, MBA, MS, Douglas Londono, PhD, Yeison Ortiz, BS, Anna Wang, PhD, Nathan Markward, PhD, MPH, and Steven Emrick, BS,…

At ISPOR 2025 in Montreal, PurpleLab presented a research poster titled “Intersectional Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA) for Social Determinants of Health and Pregnancy Outcomes.” The study, conducted by Anna Wang, PhD, Francis Concannon, BS, Daria Eremina, PhD, and Douglas Londono, PhD, applied MAIHDA to analyze how overlapping social factors influence…